지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.1
- 수록면
- 1 - 10 (10page)
이용수
초록· 키워드
오류제보하기
Background: The occurrence of hepatocellular carcinoma (HCC) is a major concern during antiviral therapy for chronic hepatitis B. There are conflicting opinions regarding the effects of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) on HCC prevention. We assessed these two antiviral medications for preventing HCC in treatment-naïve patients with chronic hepatitis B. Methods: We conducted a retrospective cohort study using nationwide claims data from the Korea Health Insurance Review and Assessment Service. We included 55,473 treatment-naïve adult cases where ETV or TDF treatment was started between 2013 and 2017 (cohort 1). The ETV and TDF groups were matched 1:2 based on age, sex, comorbidities, hospital type, and index date year. Patients were followed up until December 2018. The outcome was the development of HCC. Subgroup analyses were conducted according to sex, age, hospital type and the presence of cirrhosis. We also compared the outcomes of patients who had started antiviral therapy during the 2012–2014 period (cohort 2). Results: The matched participants (18,491 in the ETV and 36,982 in the TDF groups) were a part of the study for, on average, 41.2 months. The incidence of HCC did not differ significantly between the ETV (1.46 per 100 patient-years) and the TDF (1.36 per 100 patient-years) treatments (hazard ratio, 0.93; 95% confidence interval, 0.86–1.01; P = 0.081). By contrast, HCC incidence was significantly higher in the ETV group than tenofovir group of cohort 2. Conclusion: In patients with chronic hepatitis B, the ETV treatment did not result in a higher rate of HCC than the TDF treatment.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
Clinical and Molecular Hepatology
2021 .01
-
Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization
Journal of Liver Cancer
2019 .01
-
Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
Clinical and Molecular Hepatology
2017 .01
-
The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency ablation for hepatitis B virus-related hepatocellular carcinoma
Journal of Liver Cancer
2021 .09
-
Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
Gut and Liver
2017 .01
-
Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis
Gut and Liver
2020 .01
-
Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B
Gut and Liver
2020 .01
-
The efficacy of Tenofovir-based therapy in patients showing suboptimal response to Entecavir-Adefovr combination therapy
Clinical and Molecular Hepatology
2016 .01
-
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
Clinical and Molecular Hepatology
2015 .01
-
Gene expression patterns of Etv5 and Etv6 in molar tooth germs at the cap stage
대한구강해부학회지
2017 .12
-
Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma
Gut and Liver
2020 .01
-
Management of Antiviral Resistance in Chronic Hepatitis B
Gut and Liver
2017 .01
-
Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment
Clinical and Molecular Hepatology
2016 .01
-
Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study
Clinical and Molecular Hepatology
2024 .07
-
Risk score model for the development of hepatocellular carcinoma in treatment-naive patients receiving oral antiviral treatment for chronic hepatitis B
Clinical and Molecular Hepatology
2017 .06
-
Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: Two cases
Clinical and Molecular Hepatology
2016 .01
-
Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
Gut and Liver
2021 .01
-
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection
Clinical and Molecular Hepatology
2022 .07
-
Efficacy of prolonged entecavir monotherapy for partial virologic response to entecavir in treatment-naïve chronic hepatitis B patients
Clinical and Molecular Hepatology
2015 .01
-
Role of Shear Wave Elastography in Evaluating the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
Gut and Liver
2017 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0